15. Maintenance treatment in acute myeloid leukemia

  1. Ross Pinkerton MB, BCh, BaO, MD Executive Director, Division of Oncology2,
  2. Ananth Shankar MD, FRCPCH Consultant in Paediatric and Adolescent Oncology3 and
  3. Katherine K. Matthay BA, MD Mildred V. Strouss Professor of Translational Oncology, Director, Pediatric Hematology-Oncology4
  1. Ananth Shankar

Published Online: 8 MAY 2013

DOI: 10.1002/9781118625309.ch15

Evidence-Based Pediatric Oncology

Evidence-Based Pediatric Oncology

How to Cite

Shankar, A. (2013) Maintenance treatment in acute myeloid leukemia, in Evidence-Based Pediatric Oncology (eds R. Pinkerton, A. Shankar and K. K. Matthay), John Wiley & Sons, Ltd, Oxford. doi: 10.1002/9781118625309.ch15

Editor Information

  1. 2

    Royal Children's Hospital, Children's Health Queensland, Brisbane, QLD, Australia

  2. 3

    University College London Hospitals NHS Foundation Trust London, UK

  3. 4

    Department of Pediatrics, UCSF School of Medicine and, UCSF Benioff Children's Hospital, San Francisco, CA, USA

Author Information

  1. University College London Hospitals NHS Foundation Trust, London, UK

Publication History

  1. Published Online: 8 MAY 2013
  2. Published Print: 20 MAY 2013

ISBN Information

Print ISBN: 9780470659649

Online ISBN: 9781118625309

SEARCH

Keywords:

  • acute myeloid leukemia (AML);
  • children;
  • maintenance treatment (MT);
  • postremission;
  • randomized trial;
  • survival outcome

Summary

The use of postremission low-dose maintenance treatment (MT) in childhood acute myeloid leukemia (AML) has yielded mixed results. This chapter provides a summary of previous studies. The studies by Perel et al. and Wells et al. suggest that MT does not appear to improve overall survival (OS). The acute promyelocytic leukemia (APL) 93 trial was a randomized European study evaluating postremission therapy for patients with APL. A later study, the GIMEMA-AIEOPAIDA trial, also evaluated the benefit of MT in childhood AML. MT with ATRA combined with CT improved survival outcome in children with APL although no conclusion can be drawn on the advantage of MT in APL due to early closure of the control arm.